Search
for
Sort by
Research 301–330 of 1000+
- Use of an alternative method to evaluate erythema severity in a clinical trial: difference in vehicle response with evaluation of baseline and postdose photographs for effect of oxymetazoline cream 1·0% for persistent erythema of rosacea in a phase IV study
- Evaluating the Therapeutic Potential of Ritlecitinib for the Treatment of Alopecia Areata
- Predicting hair cortisol levels with hair pigmentation genes: a possible hair pigmentation bias
- Combining 675 nm Laser with Isotretinoin for Enhanced Acne Vulgaris Treatment Outcomes
- Association of hirsutism and anthropometric profiles with sexual dysfunction and anxiety levels in infertile Indonesian women with polycystic ovarian syndrome
- Hair Loss Profiles and Ritlecitinib Efficacy in Patients with Alopecia Areata: Post Hoc Analysis of the ALLEGRO Phase 2b/3 Study
- A comparative study of fractional CO2 laser with topical triamcinolone acetonide versus intralesional triamcinolone acetonide in the treatment of alopecia areata
- Can oral minoxidil be the game changer in androgenetic alopecia? A comprehensive review and meta-analysis comparing topical and oral minoxidil for treating androgenetic alopecia
- Epidemiology, Diagnosis and Management of Alopecia Areata: An Asia‐Pacific Modified Delphi Expert Panel Recommendations
- Pilot Clinical Evaluation of a Hyaluronic Acid– and Hydrogen Peroxide–Based Gel in the Management of Folliculitis: An Open-Label, Post-Marketing Study
- Hair density response to photobiomodulation in canine alopecia X is measured reliably with an ordinal scale: a randomized, controlled, double-blind study
- Two‐dimensional planimetry for alopecia areata severity evaluation compared with severity of alopecia tool: A pilot study
- The Notch Intracellular Domain Has an RBPj-Independent Role during Mouse Hair Follicular Development
- Long‐term safety and efficacy of ritlecitinib in adults and adolescents with alopecia areata and at least 25% scalp hair loss: Results from the ALLEGRO‐LT phase 3, open‐label study
- Efficacy and safety of ritlecitinib in Asian patients with alopecia areata: A subgroup analysis of the ALLEGRO phase 2b/3 trial
- Is polycystic ovary syndrome a risk factor for depression and anxiety?: a cross-sectional study
- Intradermal platelet-rich plasma for the treatment of melasma: A clinical and dermoscopic evaluation in dark skin
- Determination of serum 25-hydroxyvitamin D levels in patients with alopecia areata and their comparison with levels in healthy controls: A cross-sectional study
- Serenoa repens (Saw palmetto) for Lower Urinary Tract Symptoms (LUTS): The Evidence for Efficacy and Safety of Lipidosterolic Extracts. Part I
- Impact of Disease History on the Efficacy of Ritlecitinib in Patients With Alopecia Areata: Post Hoc Analysis of the ALLEGRO Phase 2b/3 Study
- Holistic management of Alopecia areata (~Indralupta) using Pracchana karma with derma-roller and Ayurveda intervention: A case report
- Serum Granulysin Levels in Vitiligo and Alopecia Areata: A Potential Biomarker for Disease Activity and Dermoscopic Evaluation
- An Automatic AI‐Based Algorithm That Grades the Scalp Surface Exfoliating Process From Video Imaging. Application to Dandruff Severity and Its Validation on Subjects of Different Ages and Ethnicities
- Analysis of 72,469 UK Biobank exomes links rare variants to male-pattern hair loss
- II Consensus of the Brazilian Society of Dermatology for the treatment of alopecia areata
- Baricitinib Demonstrates Rapid Action Within Just 2 Months of Treatment in Severe and Unresponsive Alopecia Areata: A Case Report
- The Versatile Applications of Triple‐Wavelength Diode Laser (810, 940, and 1060 nm) in Aesthetic Treatments, Follicular Disorders, and Chronic Inflammatory Conditions in the Asian Population: Case Report Collection
- Dupilumab therapy for alopecia areata in pediatric patients with concomitant atopic dermatitis
- Targeting the Janus Kinase Family in Autoimmune Skin Diseases
- Efficacy and Safety of Baricitinib in Patients with Severe Alopecia Areata over 52 Weeks of Continuous Therapy in Two Phase III Trials (BRAVE-AA1 and BRAVE-AA2)